Literature DB >> 20157291

Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE.

Marina O Ziehn1, Andrea A Avedisian, Seema Tiwari-Woodruff, Rhonda R Voskuhl.   

Abstract

Over half of multiple sclerosis (MS) patients experience cognitive deficits, including learning and memory dysfunction, and the mechanisms underlying these deficits remain poorly understood. Neuronal injury and synaptic loss have been shown to occur within the hippocampus in other neurodegenerative disease models, and these pathologies have been correlated with cognitive impairment. Whether hippocampal abnormalities occur in MS models is unknown. Using experimental autoimmune encephalomyelitis (EAE), we evaluated hippocampal neurodegeneration and inflammation during disease. Hippocampal pathology began early in EAE disease course, and included decreases in CA1 pyramidal layer volume, loss of inhibitory interneurons and increased cell death of neurons and glia. It is interesting to note that these effects occurred in the presence of chronic microglial activation, with a relative paucity of infiltrating blood-borne immune cells. Widespread diffuse demyelination occurred in the hippocampus, but there was no significant decrease in axonal density. Furthermore, there was a significant reduction in pre-synaptic puncta and synaptic protein expression within the hippocampus, as well as impaired performance on a hippocampal-dependent spatial learning task. Our results demonstrate that neurodegenerative changes occur in the hippocampus during autoimmune-mediated demyelinating disease. This work establishes a preclinical model for assessing treatments targeted toward preventing hippocampal neuropathology and dysfunction in MS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20157291      PMCID: PMC3033772          DOI: 10.1038/labinvest.2010.6

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  47 in total

1.  Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis.

Authors:  Bing Zhu; Liqing Luo; G R Wayne Moore; Donald W Paty; Max S Cynader
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

2.  Thalamic neurodegeneration in multiple sclerosis.

Authors:  Alberto Cifelli; Marzena Arridge; Peter Jezzard; Margaret M Esiri; Jacqueline Palace; Paul M Matthews
Journal:  Ann Neurol       Date:  2002-11       Impact factor: 10.422

3.  Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis.

Authors:  Jerome R Wujek; Carl Bjartmar; Edward Richer; Richard M Ransohoff; Min Yu; Vincent K Tuohy; Bruce D Trapp
Journal:  J Neuropathol Exp Neurol       Date:  2002-01       Impact factor: 3.685

4.  Normal CNS myelination in transgenic mice overexpressing MHC class I H-2L(d) in oligodendrocytes.

Authors:  B Fuss; F S Afshari; R J Colello; W B Macklin
Journal:  Mol Cell Neurosci       Date:  2001-08       Impact factor: 4.314

5.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

Authors:  Y Ge; R I Grossman; J K Udupa; L Wei; L J Mannon; M Polansky; D L Kolson
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

6.  Relations between brain pathology and temporal lobe epilepsy.

Authors:  Xia Zhang; Shu-Sen Cui; Amy E Wallace; Darren K Hannesson; Larry C Schmued; Deborah M Saucier; William G Honer; Michael E Corcoran
Journal:  J Neurosci       Date:  2002-07-15       Impact factor: 6.167

7.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

Authors:  M Filippi; M Bozzali; M Rovaris; O Gonen; C Kesavadas; A Ghezzi; V Martinelli; R I Grossman; G Scotti; G Comi; A Falini
Journal:  Brain       Date:  2003-02       Impact factor: 13.501

8.  Estrogen receptor alpha mediates estrogen's immune protection in autoimmune disease.

Authors:  Hong-biao Liu; Kyi Kyi Loo; Karen Palaszynski; Judith Ashouri; Dennis B Lubahn; Rhonda R Voskuhl
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

9.  Overexpression of the 3'-untranslated region of myelin proteolipid protein mRNA leads to reduced expression of endogenous proteolipid mRNA.

Authors:  Barbara S Mallon; Wendy B Macklin
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

10.  The chronology of age-related spatial learning impairment in two rat strains, as tested by the Barnes maze.

Authors:  Graham L Barrett; Antoinette Bennie; Jennifer Trieu; Sophie Ping; Christine Tsafoulis
Journal:  Behav Neurosci       Date:  2009-06       Impact factor: 1.912

View more
  81 in total

1.  Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.

Authors:  Stefan M Gold; Kyle C Kern; Mary-Frances O'Connor; Michael J Montag; Aileen Kim; Ye S Yoo; Barbara S Giesser; Nancy L Sicotte
Journal:  Biol Psychiatry       Date:  2010-06-19       Impact factor: 13.382

2.  Automated measurement of nerve fiber density using line intensity scan analysis.

Authors:  Aaron Sathyanesan; Tatsuya Ogura; Weihong Lin
Journal:  J Neurosci Methods       Date:  2012-02-28       Impact factor: 2.390

3.  Chronic demyelination-induced seizures.

Authors:  Andrew S Lapato; Jenny I Szu; Jonathan P C Hasselmann; Anna J Khalaj; Devin K Binder; Seema K Tiwari-Woodruff
Journal:  Neuroscience       Date:  2017-01-30       Impact factor: 3.590

Review 4.  Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  J Neural Transm (Vienna)       Date:  2015-05-06       Impact factor: 3.575

5.  Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis.

Authors:  Noriko Itoh; Roy Kim; Mavis Peng; Emma DiFilippo; Hadley Johnsonbaugh; Allan MacKenzie-Graham; Rhonda R Voskuhl
Journal:  J Neuroimmunol       Date:  2016-10-03       Impact factor: 3.478

Review 6.  Inflammation induced neurological handicap processes in multiple sclerosis: new insights from preclinical studies.

Authors:  Klaus G Petry; Bruno Brochet; Vincent Dousset; Jean Rodolphe Vignes; Claudine Boiziau
Journal:  J Neural Transm (Vienna)       Date:  2010-06-23       Impact factor: 3.575

7.  Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology.

Authors:  Elizabeth E Spangenberg; Rafael J Lee; Allison R Najafi; Rachel A Rice; Monica R P Elmore; Mathew Blurton-Jones; Brian L West; Kim N Green
Journal:  Brain       Date:  2016-02-26       Impact factor: 13.501

8.  Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis.

Authors:  Patrizia LoPresti
Journal:  Neurochem Res       Date:  2014-12-07       Impact factor: 3.996

9.  Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling.

Authors:  Stefan M Gold; Mary-Frances O'Connor; Raja Gill; Kyle C Kern; Yonggang Shi; Roland G Henry; Daniel Pelletier; David C Mohr; Nancy L Sicotte
Journal:  Hum Brain Mapp       Date:  2012-07-30       Impact factor: 5.038

Review 10.  Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis.

Authors:  Robert Nisticò; Francesco Mori; Marco Feligioni; Ferdinando Nicoletti; Diego Centonze
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-12-02       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.